Trodat 1 SPECT and Dopamine Polymorphism
The study population will include 100 parkinsonian patients in early stage of disease, with total duration not exeeding 5 years.
The patients will undergo neurologic examination and evaluation of disease severity using the unified PD rating scale. Subsequently a brain SPECT will be performed using Tc-99m-Trodat1.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Association of Polymorphism in Genes Associated With Control of Dopamine Levels in Parkinson's Disease and Tc-99m-Trodat-1 SPECT Imaging.|
- Disease severity versus genetic polymorphism [ Time Frame: 1 year ] [ Designated as safety issue: No ]Correlation of disease severity with polymorphism and with striatal affinity to the DAT ligand.
- Severity of PD compared to specific striatal DAT activity as measures by Tc-99m Trodat SPECT. [ Time Frame: 1 year ] [ Designated as safety issue: No ]For each striatal ROI, mean counts will be measured, and specific TRODAT uptake will be calculated, according to the following formula: Specific TRODAT uptake = (mean activity in ROI - mean Activity in occipital cortex) / mean Activity in occipital cortex).
Biospecimen Retention: Samples With DNA
|Study Start Date:||August 2011|
|Study Completion Date:||August 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
Early onset of disease
Please refer to this study by its ClinicalTrials.gov identifier: NCT01381302
|Edith Wolfson medical Center|
|Holon, Israel, 58100|
|Principal Investigator:||Mordechai Lorberboym, MD||Edith Wolfson Medical Center|